Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
作者： Christopher A. Barker , Andrew J. Bishop , Maria Chang , Kathryn Beal , Timothy A. Chan
DOI: 10.1016/J.IJROBP.2013.02.012
关键词:
摘要: Purpose Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, it can modulate the biologic effects of radiation therapy (RT). We investigated whether VA use during RT for GB was associated overall survival (OS). Methods Materials Medical records 544 adults were retrospectively reviewed. Analyses performed determine association Radiation Therapy Oncology Group recursive partitioning analysis (RTOG RPA) class, seizure history, concurrent temozolomide (TMZ) AED OS. Results Seizures before end noted in 217 (40%) patients, 403 (74%) taking RT; 29 (7%) VA. Median OS 16.9 months (vs 13.6 another AED, P =.16). Among RT, ( =.047; hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.27-1.07), RTOG RPA class =.26). When restricted who received TMZ, marginally =.057; HR, 0.54; CI, −0.09 1.17), independently history. Conclusions improved OS, RPA, TMZ use. Further studies treatment that combines HDAC inhibitors are warranted.
osti.gov
sci-hub.se 参考文章(21)
Stefan Oberndorfer, Maria Piribauer, Christine Marosi, Heinz Lahrmann, Peter Hitzenberger, Wolfgang Grisold, P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. Journal of Neuro-oncology. ,vol. 72, pp. 255- 260 ,(2005) , 10.1007/S11060-004-2338-2
W. J. Curran, C. B. Scott, J. Horton, J. S. Nelson, A. S. Weinstein, A. J. Fischbach, C. H. Chang, M. Rotman, S. O. Asbell, R. E. Krisch, D. F. Nelson, Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials Journal of the National Cancer Institute. ,vol. 85, pp. 704- 710 ,(1993) , 10.1093/JNCI/85.9.704
, Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature. ,vol. 455, pp. 1061- 1068 ,(2008) , 10.1038/NATURE07385
Sara Eyal, Boris Yagen, Eyal Sobol, Yoram Altschuler, Miriam Shmuel, Meir Bialer, The Activity of Antiepileptic Drugs as Histone Deacetylase Inhibitors Epilepsia. ,vol. 45, pp. 737- 744 ,(2004) , 10.1111/J.0013-9580.2004.00104.X
Jeremy D. Ruben, Michael Dally, Michael Bailey, Robin Smith, Catriona A. McLean, Pasqual Fedele, Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. International Journal of Radiation Oncology Biology Physics. ,vol. 65, pp. 499- 508 ,(2006) , 10.1016/J.IJROBP.2005.12.002
Prakash Chinnaiyan, David Cerna, William E. Burgan, Katie Beam, Eli S. Williams, Kevin Camphausen, Philip J. Tofilon, Postradiation Sensitization of the Histone Deacetylase Inhibitor Valproic Acid Clinical Cancer Research. ,vol. 14, pp. 5410- 5415 ,(2008) , 10.1158/1078-0432.CCR-08-0643
Hong-Chieh Tsai, Kuo-Chen Wei, Chi-Neu Tsai, Ying-Cheng Huang, Pin-Yuan Chen, Shu-Mei Chen, Yu-Jen Lu, Shih-Tseng Lee, Effect of valproic acid on the outcome of glioblastoma multiforme. British Journal of Neurosurgery. ,vol. 26, pp. 347- 354 ,(2012) , 10.3109/02688697.2011.638996
Kevin Camphausen, David Cerna, Tamalee Scott, Mary Sproull, William E. Burgan, Michael A. Cerra, Howard Fine, Philip J. Tofilon, Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid International Journal of Cancer. ,vol. 114, pp. 380- 386 ,(2005) , 10.1002/IJC.20774
D. Thotala, K. Sweeney, K. Leahy, R. Hu, D. Hallahan, Valproic Acid Enhances Radiation Therapy by Protecting Normal Hippocampal Neurons and Sensitizing Malignant Glioblastoma Cells In Vivo and In Vitro International Journal of Radiation Oncology Biology Physics. ,vol. 81, ,(2011) , 10.1016/J.IJROBP.2011.06.919
M. Weller, T. Gorlia, J. G. Cairncross, M. J. van den Bent, W. Mason, K. Belanger, A. A. Brandes, U. Bogdahn, D. R. Macdonald, P. Forsyth, A. O. Rossetti, D. Lacombe, R.- O. Mirimanoff, C. J. Vecht, R. Stupp, Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma Neurology. ,vol. 77, pp. 1156- 1164 ,(2011) , 10.1212/WNL.0B013E31822F02E1